"""

Question: 1101

Evidence: The newly reported integrase sequences have been submitted to GenBank under accession numbers OM877162–OM877261. Overall, we recruited 103 individuals tested positive for the first-time for HIV-1 infection.

Rationale: The paper explicitly states that "newly reported integrase sequences" have been submitted to GenBank, indicating the data is previously unpublished. Furthermore, the study describes the recruitment of 103 individuals, which is part of the original research being reported.

Answer: Yes

"""

"""
Question: 1102

Evidence: The newly reported integrase sequences have been submitted to GenBank under accession numbers OM877162–OM877261. For the remaining 100 sequences representing our final study population, the HIV-1 subtype distribution was as follows: CRF02_AG (46%), A1 (17%), D (7%), CRF45_cpx (5%), G (7%), CRF37_cpx (7%), H (4%), CRF11_cpx (4%), F2 (2%), CRF06_cpx (1%), CRF09_cpx (1%), and Unknown (6%).

Rationale: The paper directly reports the generation and analysis of HIV sequences, specifically integrase gene sequences, from 100 study participants. It provides the GenBank accession numbers for these sequences and details their subtype distribution.

Answer: Yes

"""

"""
Question: 1103

Evidence: NA

Rationale: After a thorough review of the provided paper content, there is no mention of in vitro passage experiments being conducted. The study focuses on genotyping viral sequences from recently diagnosed, treatment-naive patients.

Answer: No

"""

"""
Question: 1104

Evidence: Recent phenotypic assessments of this mutation in context of CRF02_AG viruses showed a fold change in EC50 of 1.1, 1.9 and 2.4 for raltegravir, dolutegravir and elvitegravir, respectively,6 stressing the need for more surveillances of this mutation in a HIV-1 non-B context.

Rationale: The paper does not report conducting its own in vitro antiretroviral susceptibility tests. It cites phenotypic data (fold change in EC50) from another study (reference 6) to provide context for the mutations it found, but this is not data generated by the authors of this paper.

Answer: No

"""

"""
Question: 2101

Evidence: The newly reported integrase sequences have been submitted to GenBank under accession numbers OM877162–OM877261.

Rationale: The paper explicitly provides the GenBank accession numbers (OM877162–OM877261) under which the newly generated HIV integrase sequences have been deposited.

Answer: Yes

"""

"""
Question: 2102

Evidence: The newly reported integrase sequences have been submitted to GenBank under accession numbers OM877162–OM877261.

Rationale: The paper states that the sequences submitted to GenBank are "newly reported integrase sequences" from the study population. There is no mention of any sequences from laboratory HIV isolates. All sequences appear to be from clinical samples from recently diagnosed patients in Gabon.

Answer: Yes

"""

"""
Question: 2103

Evidence: The newly reported integrase sequences have been submitted to GenBank under accession numbers OM877162–OM877261.

Rationale: The paper directly states the GenBank accession numbers for the sequences it reports, which are OM877162 to OM877261.

Answer: OM877162–OM877261

"""

"""
Question: 2202

Evidence: Two primary drug resistance mutations, T97A and E157Q, were found in 4 (4%) and 5 (5%) of the sequences, respectively. Two additional mutations, L74M and L74I, considered as potentially associated with resistance to INSTIs were identified at rates of 3% and 21%, respectively.

Rationale: The paper reports the prevalence of specific mutations (T97A, E157Q, L74M, L74I) across the study population. However, it does not provide lists of all mutations for each individual sequenced HIV isolate. It reports aggregate frequencies.

Answer: No

"""

"""
Question: 2301

Evidence: Overall, we recruited 103 individuals tested positive for the first-time for HIV-1 infection.

Rationale: The paper explicitly states that the study was conducted on individuals infected with HIV-1.

Answer: HIV-1

"""

"""
Question: 2302

Evidence: For the remaining 100 sequences representing our final study population, the HIV-1 subtype distribution was as follows: CRF02_AG (46%), A1 (17%), D (7%), CRF45_cpx (5%), G (7%), CRF37_cpx (7%), H (4%), CRF11_cpx (4%), F2 (2%), CRF06_cpx (1%), CRF09_cpx (1%), and Unknown (6%).

Rationale: The paper provides a detailed breakdown of the HIV-1 subtypes found in the 100 sequenced viruses from the study population.

Answer: CRF02_AG, A1, D, CRF45_cpx, G, CRF37_cpx, H, CRF11_cpx, F2, CRF06_cpx, CRF09_cpx, Unknown

"""

"""
Question: 2303

Evidence: These 100 sequences, that cover at least amino acid positions 66 to 263 of the HIV integrase gene (Figure 1), were interpreted using the HIV French Resistance algorithm.

Rationale: The paper clearly states that the sequenced gene is the HIV integrase gene.

Answer: integrase

"""

"""
Question: 2304

Evidence: These 100 sequences, that cover at least amino acid positions 66 to 263 of the HIV integrase gene (Figure 1), were interpreted using the HIV French Resistance algorithm.

Rationale: The paper specifically states that the sequences are of the HIV integrase gene. The pol gene includes integrase, protease, and reverse transcriptase. Since only the integrase part of pol was sequenced, the paper reports results of HIV pol sequences (specifically the integrase region).

Answer: Yes

"""

"""
Question: 2401

Evidence: The study was implemented in the southern region of the country in the Haut-Ogooué Province that includes Franceville and the neighbouring sub-districts.

Rationale: The paper describes the study location as being in the Haut-Ogooué Province of Gabon, which is in Central Africa.

Answer: Gabon, Central Africa

"""

"""
Question: 2402

Evidence: NA

Rationale: The paper does not mention the specific years during which the samples were obtained. It mentions the study was approved by an ethics committee in 2013 (0011/2013/SG/CNE), but this does not specify the sample collection period.

Answer: NA

"""

"""
Question: 2502

Evidence: NA

Rationale: The paper describes drug resistance genotyping and sequencing but does not specify the sequencing technology used (e.g., Sanger or NGS).

Answer: NA

"""

"""
Question: 2503

Evidence: NA

Rationale: The paper describes drug resistance genotyping and sequencing but does not specify the sequencing technology used (e.g., Sanger or NGS).

Answer: NA

"""

"""
Question: 2504

Evidence: NA

Rationale: The paper does not mention any process of cloning samples prior to sequencing.

Answer: No

"""

"""
Question: 2505

Evidence: NA

Rationale: The paper does not mention the use of single genome sequencing.

Answer: No

"""

"""
Question: 2506

Evidence: NA

Rationale: The paper does not mention the use of molecular cloning.

Answer: No

"""

"""
Question: 2601

Evidence: NA

Rationale: The paper does not explicitly state the source of the viral material used for sequencing (e.g., plasma or PBMCs).

Answer: NA

"""

"""
Question: 2602

Evidence: NA

Rationale: The paper does not explicitly state the source of the viral material used for sequencing (e.g., plasma or PBMCs).

Answer: NA

"""

"""
Question: 2603

Evidence: NA

Rationale: The paper does not state how many samples underwent plasma virus sequencing, as it does not specify the sample source.

Answer: NA

"""

"""
Question: 2604

Evidence: NA

Rationale: The paper does not state how many samples underwent PBMC virus sequencing, as it does not specify the sample source.

Answer: NA

"""

"""
Question: 2605

Evidence: Overall, we recruited 103 individuals tested positive for the first-time for HIV-1 infection.

Rationale: The individuals were recently diagnosed and first-time positive for HIV-1, indicating active HIV replication at the time of sampling.

Answer: Yes

"""

"""
Question: 2606

Evidence: They target the strand transfer reaction of the HIV proviral DNA 3′ ends to the cellular DNA and thus inhibit viral replication.1

Rationale: The paper discusses proviral DNA in the context of how INSTIs work, but it does not state that the sequences reported in the study were obtained from the proviral DNA reservoir. The source of the sequenced genetic material is not specified.

Answer: NA

"""

"""
Question: 2701

Evidence: the median age was 37 years (IQR 28–44).

Rationale: The paper provides the median age and interquartile range of the study participants, which are all adults (28-44 years). There is no mention of infants or children.

Answer: No

"""

"""
Question: 2702

Evidence: NA

Rationale: The paper describes a observational study of recently diagnosed individuals. There is no mention of participants being involved in a clinical trial.

Answer: No

"""

"""
Question: 2703

Evidence: NA

Rationale: The paper describes a observational study of recently diagnosed individuals. There is no mention of participants being involved in a clinical trial.

Answer: No

"""

"""
Question: 3101

Evidence: Overall, we recruited 103 individuals tested positive for the first-time for HIV-1 infection. Drug resistance genotyping was successfully carried out for all and three participants were excluded because of epidemiological relationship indicated by the obtained phylogeny. For the remaining 100 sequences representing our final study population.

Rationale: The paper states that 103 individuals were recruited and tested positive. Genotyping was successful for all 103, but 3 were later excluded from analysis, leaving 100 sequences in the final study population. Therefore, samples were obtained from 103 individuals for sequencing.

Answer: 103

"""

"""
Question: 3102

Evidence: Drug resistance genotyping was successfully carried out for all.

Rationale: The paper explicitly states that drug resistance genotyping, which involves HIV sequencing, was successfully carried out for all 103 recruited individuals.

Answer: Yes

"""

"""
Question: 4101

Evidence: All participants were treatment naive and reported no history of ARV exposure.

Rationale: The paper clearly states that all participants in the study were treatment-naive and had no history of antiretroviral drug exposure.

Answer: Yes

"""

"""
Question: 4102

Evidence: All participants were treatment naive and reported no history of ARV exposure.

Rationale: The paper explicitly states that all participants were treatment-naive, meaning none had previously received ARV drugs.

Answer: No

"""

"""
Question: 4103

Evidence: All participants were treatment naive and reported no history of ARV exposure.

Rationale: The paper states that all participants were ART-naive. It does not report any sequences from ART-experienced individuals.

Answer: No

"""

"""
Question: 4104

Evidence: Overall, we recruited 103 individuals tested positive for the first-time for HIV-1 infection. All participants were treatment naive and reported no history of ARV exposure.

Rationale: The paper states that all 103 recruited individuals were treatment-naive.

Answer: 103

"""

"""
Question: 4105

Evidence: All participants were treatment naive and reported no history of ARV exposure.

Rationale: The paper provides a clear and complete ART history for all individuals: they were all treatment-naive with no history of ARV exposure.

Answer: Yes

"""

"""
Question: 4201

Evidence: Two primary drug resistance mutations, T97A and E157Q, were found in 4 (4%) and 5 (5%) of the sequences, respectively, resulting in an overall drug resistance prevalence of 9%.

Rationale: The paper reports the prevalence of drug resistance mutations in a population of recently diagnosed, treatment-naive individuals. This constitutes transmitted HIV drug resistance.

Answer: Yes

"""

"""
Question: 4202

Evidence: Two primary drug resistance mutations, T97A and E157Q, were found in 4 (4%) and 5 (5%) of the sequences, respectively, resulting in an overall drug resistance prevalence of 9%.

Rationale: The paper reports the prevalence of drug resistance mutations in a population of ART-naive individuals initiating treatment. This is the definition of pretreatment HIV drug resistance.

Answer: Yes

"""

"""
Question: 4301

Evidence: All participants were treatment naive and reported no history of ARV exposure.

Rationale: The paper explicitly states that all participants were treatment-naive and had no history of ARV exposure. Therefore, no drug classes were received by the individuals in the study.

Answer: None

"""

"""
Question: 4302

Evidence: All participants were treatment naive and reported no history of ARV exposure.

Rationale: The paper explicitly states that all participants were treatment-naive, meaning they had not received any antiretroviral drugs, including integrase inhibitors.

Answer: No

"""

"""
Question: 4303

Evidence: All participants were treatment naive and reported no history of ARV exposure.

Rationale: The paper explicitly states that all participants were treatment-naive, meaning they had not received any antiretroviral drugs, including protease inhibitors.

Answer: No

"""

"""
Question: 4304

Evidence: All participants were treatment naive and reported no history of ARV exposure.

Rationale: Since all participants were treatment-naive, none of them received any ART.

Answer: Yes

"""

"""
Question: 4305

Evidence: In this study, we investigated the role of existing viral mutations among INSTI-naive HIV-1 non-B-infected individuals in Gabon.

Rationale: The paper directly refers to the study population as "INSTI-naive".

Answer: Yes

"""

"""
Question: 4403

Evidence: All participants were treatment naive and reported no history of ARV exposure.

Rationale: Since all participants were treatment-naive, none of them received any ART regimens.

Answer: 0

"""

"""
Question: 4404

Evidence: All participants were treatment naive and reported no history of ARV exposure.

Rationale: Since all participants were treatment-naive, none of them received any ART regimens.

Answer: 0

"""

"""
Question: 4405

Evidence: All participants were treatment naive and reported no history of ARV exposure.

Rationale: Since all participants were treatment-naive, they all received the same number of ART regimens: zero.

Answer: Yes

"""

"""
Question: 4406

Evidence: All participants were treatment naive and reported no history of ARV exposure.

Rationale: Since all participants were treatment-naive, none of them received even one ART regimen.

Answer: No

"""

"""
Question: 4501

Evidence: All participants were treatment naive and reported no history of ARV exposure.

Rationale: Since all participants were treatment-naive, none of them received dolutegravir or any other ART.

Answer: 0

"""

"""
Question: 4502

Evidence: All participants were treatment naive and reported no history of ARV exposure.

Rationale: Since all participants were treatment-naive, none of them received darunavir or any other ART.

Answer: 0

"""

"""
Question: 5101

Evidence: Two primary drug resistance mutations, T97A and E157Q, were found in 4 (4%) and 5 (5%) of the sequences, respectively, resulting in an overall drug resistance prevalence of 9%.

Rationale: The paper states that the overall drug resistance prevalence was 9%. This means 9% of the 100 individuals had one or more drug resistance mutations. 9% of 100 is 9 individuals.

Answer: 9

"""

"""
Question: 5102

Evidence: Two primary drug resistance mutations, T97A and E157Q, were found in 4 (4%) and 5 (5%) of the sequences, respectively, resulting in an overall drug resistance prevalence of 9%.

Rationale: The paper identifies T97A and E157Q as primary INSTI-resistance mutations. It reports 4 sequences with T97A and 5 with E157Q. As these are the only primary INSTI-resistance mutations reported, and the paper does not specify if any individual had both, the maximum number of individuals with an INSTI-resistance mutation is 9 (4+5). The overall drug resistance prevalence of 9% (9/100) is attributed to these mutations.

Answer: 9

"""

"""
Question: 5103

Evidence: NA

Rationale: The paper focuses exclusively on mutations related to integrase strand transfer inhibitors (INSTIs). It does not mention tenofovir (TDF) or mutations associated with NRTI resistance like those for TDF.

Answer: 0

"""

"""
Question: 5104

Evidence: Two primary drug resistance mutations, T97A and E157Q, were found in 4 (4%) and 5 (5%) of the sequences, respectively. Two additional mutations, L74M and L74I, considered as potentially associated with resistance to INSTIs were identified at rates of 3% and 21%, respectively.

Rationale: The paper reports the INSTI-resistance mutations found in the study population. The primary ones are T97A and E157Q. L74M and L74I are also reported as potentially associated with resistance.

Answer: T97A, E157Q, L74M, L74I

"""

"""
Question: 6101

Evidence: NA

Rationale: The paper does not report conducting any phenotypic susceptibility tests. It only reports genotypic data and references phenotypic data from other studies.

Answer: NA

"""

"""
Question: 6102

Evidence: Recent phenotypic assessments of this mutation in context of CRF02_AG viruses showed a fold change in EC50 of 1.1, 1.9 and 2.4 for raltegravir, dolutegravir and elvitegravir, respectively,6

Rationale: The paper cites another study (reference 6) that reported EC50 values, but the authors of this paper did not perform these tests themselves. Therefore, the paper does not report its own IC/EC values.

Answer: No

"""

"""
Question: 6103

Evidence: Recent phenotypic assessments of this mutation in context of CRF02_AG viruses showed a fold change in EC50 of 1.1, 1.9 and 2.4 for raltegravir, dolutegravir and elvitegravir, respectively,6

Rationale: The paper cites another study (reference 6) that reported EC50 fold change values, but the authors of this paper did not generate this data themselves. Therefore, the paper does not report its own IC50/EC50 fold change values.

Answer: No

"""

"""
Question: 6104"""
Question: 6104

Evidence: NA

Rationale: The paper does not report conducting any phenotypic susceptibility assays. It only references results from other studies.

Answer: NA

"""

"""
Question: 6105

Evidence: NA

Rationale: The paper does not mention or report any data related to the replication capacity of the viruses studied.

Answer: No

"""

"""
Question: 6106

Evidence: Recent phenotypic assessments of this mutation in context of CRF02_AG viruses showed a fold change in EC50 of 1.1, 1.9 and 2.4 for raltegravir, dolutegravir and elvitegravir, respectively,6

Rationale: The paper cites another study (reference 6) that tested the drugs raltegravir, dolutegravir, and elvitegravir. However, the authors of this paper did not perform any phenotypic susceptibility testing themselves.

Answer: NA

"""

"""
Question: 7101

Evidence: NA

Rationale: The paper describes the analysis of naturally occurring viral sequences from patients. There is no mention of generating or studying site-directed mutants.

Answer: No

"""

"""
Question: 7102

Evidence: NA

Rationale: The paper describes a clinical study of viral sequences from patients. There is no mention of conducting in vitro passage experiments.

Answer: No

"""